Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemoradiotherapy followed by Peg-Asp-GDP for localized nasal NK/T-cell lymphoma
ChiCTR-OPC-15006263Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase, gemcitabine, cisplatin and dexamethasone in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Union Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Planned start Jun 2015; status: not yet recruiting.
02
Drugs
pegaspargasegemcitabinecisplatindexamethasone
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR-OPC-15006263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006263.